Most Read

RAG-18 is claimed to be the first saRNA therapeutic to receive ODD status. DMD and BMD  are caused by mutations in the DMD gene. The FDA grants ODD

The launch may lead to additional milestone payments, minimum sales payments, and royalties for RedHill on net sales. Talicia is the only low-dose rifabutin-based therapy which received approval

This asset is being assessed to treat patients with relapsed or refractory extensive-stage small-cell lung cancer (ES-SCLC) who have shown disease progression on or following treatment with platinum-based

This designation is a critical step in accelerating the drug’s development and review process, recognising the urgent need for new treatments in this area. Arthrosi Therapeutics founder and

ENHERTU, a HER2 directed a DXd antibody drug conjugate (ADC), was discovered by Daiichi Sankyo and is being jointly developed and commercialised by Daiichi Sankyo with AstraZeneca. The

This move comes as part of the research collaboration agreement initiated on 21 December 2021. As per the 2021 deal, Aarvik carried out the discovery and preclinical development

The vaccine candidate is a virus-like particle (VLP)-based, adjuvanted vaccine designed for active immunisation against chikungunya virus (CHIKV) infection. This expedited review process is a significant step towards

The collaboration between Persist AI and Nivagen will leverage AI-based formulation technology of Persist alongside Nivagen’s manufacturing prowess. The goal is to streamline and expedite the development and

Enzeevu is designed to improve and maintain visual acuity in patients suffering from nAMD, a condition that is a primary cause of vision impairment among individuals over 50